Reprint: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults.

By N. Stone, Jennifer G. Robinson, A. Lichtenstein, C. Bairey Merz, C. Blum, R. Eckel, A. Goldberg, D. Gordon, Daniel Levy, D. Lloyd‐Jones and 6 more. Journal of the American Pharmacists Association, 2014

2,241 citations recorded by the source corpus.

and ASCVD risk reduction, both prior to and in concert See the “2013 AHA/ACC Guideline on Lifestyle 10 for healthy adults. Drug This table the relevant relationships of authors with industry and other entities provided by the during the document development process Both compensated and uncompensated relationships reported. These relationships reviewed updated in conjunction with all meetings and conference calls of the Expert Panel during the document development process. Authors with relevant relationships during the document development process recused themselves voting on recommendations relevant to their relationships. In the spirit of full transparency, and AHA asked members to provide updates approve the version of this table, which includes current relevant relationships (2013). review the NHLBI and ACC/AHA’s current comprehensive policies for managing relationships with industry and other entities, please http://www.nhlbi.nih.gov/guidelines/cvd_adult/coi-rwi_policy.htm Per ACC/AHA policy: A person is deemed to have a significant interest in a business the paucity of evidence from nonstatin RCTs. Inherent biases of observational data are well understood and include biases in the decisions on whom to treat and who is adherent to therapy, as well as multiple measurement biases, including verification of statin use, type and dose of statin used, consistency of use over time, and outcome ascertainment. All of these problems are addressed in intent-to-treat analyses of RCTs, which is why the FDA requires well-designed RCTs to determine drug efficacy for ASCVD event reduction and common adverse effects.

Subfields: Endocrinology, Diabetes and Metabolism, Physiology, Surgery

View Paper: https://www.semanticscholar.org/paper/48579f0cd2e09d985815ee059ba4c65d7027c5b7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

In Physiology

In Surgery

Citations in the corpus

2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease (2016, background): “Guidelines for dosing and risks of statin medications have been previousl y published (24).”
Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Med (2016, background): “7 mmol/L (500 mg/dL), as these may be clues to genetic and/ or secondary causes of hypertriglyceridaemia.(25) One reason among”